← Back to Search

CK2 Inhibitor

CX-4945 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Cylene Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year - assessed throughout all cycles of participation
Awards & highlights

Study Summary

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year (assessed at cycle 1).
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year (assessed at cycle 1). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety
Secondary outcome measures
Assess for efficacy response
Establish the recommended Phase 2 dose
Pharmacokinetic and pharmacodynamic assessments.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CX-4945Experimental Treatment1 Intervention
CX-4945 oral formulation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Silmitasertib
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Cylene PharmaceuticalsLead Sponsor
5 Previous Clinical Trials
165 Total Patients Enrolled
1 Trials studying Multiple Myeloma
55 Patients Enrolled for Multiple Myeloma
Study DirectorStudy DirectorCylene Pharmaceuticals
1,214 Previous Clinical Trials
499,492 Total Patients Enrolled
25 Trials studying Multiple Myeloma
7,508 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
2010. "Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01199718.
All > Myeloma
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top